Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancerSylvie M. Guichard, Martin Pass, Zoë Howard et al.|Cancer Research|2012Cited by 17
Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) modelsM.J. O’Connor, J.F. Liu, Zhongwu Lai et al.|European Journal of Cancer|2016Cited by 3